Monday 6-9-2014 Inovio Pharmaceuticals (INO) $INO
Post# of 90
Posted On: 06/09/2014 6:24:01 PM
Monday 6-9-2014 Inovio Pharmaceuticals (INO) $INO opened at 9.89 hitting the high price of 10.80 and a day low of 9.85 with a total volume of 3,413,431. INO had a previous close of 9.85 and has been seeing an average volume of 1,237,224.
Overall Average: 32% Buy
Recent stock forum discussions about INO http://investorshangout.com/search?q=INO&...mp;yt0=Go!
Today's Top Biotech Stocks: GW Pharmaceuticals, Inovio Pharmaceuticals and Novavax, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Jun 06, 7:45AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for GW Pharmaceuticals , Inovio Pharmaceuticals and Novavax Shares of GW Pharmaceuticals are up close to 6% in premarket trading this morning after the... (full story)
Inovio Pharmaceuticals sets 5 June 2014 as its reverse common stock split date
M2 - Mon Jun 02, 6:02AM CDT
Vaccines company Inovio Pharmaceuticals (NYSE MKT:INO) disclosed on Friday that its one for four reverse stock split shall become effective at 17:00 on 5 June 2014. (full story)
Today's Top Stories in Health Care: Inovio Pharmaceuticals, MannKind Corp. NewLink Genetics and Retr
George Budwell, The Motley Fool - Motley Fool - Fri May 30, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Inovio Pharmaceuticals , MannKind Corp. , NewLink Genetics and Retrophin . Inovio announces date for reverse split Clinical stage vaccinemaker... (full story)
Inovio Pharmaceuticals to implement its reverse common stock split on 5 June 2014
M2 - Fri May 30, 3:41AM CDT
Vaccines company Inovio Pharmaceuticals (NYSE MKT:INO) on Friday said that its one-for-four reverse stock split will become effective at 17:00 on 5 June 2014. (full story)
Inovio Pharmaceuticals Announces Reverse Stock Split Date
PR Newswire - Fri May 30, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014. The common stock will continue to trade under the symbol "INO." (full story)
Inovio Pharmaceuticals divests its animal health assets through its subsidiary
M2 - Tue May 27, 4:34AM CDT
Vaccines company Inovio Pharmaceuticals (NYSE MKT:INO) reported on Tuesday the completion of the sale of its animal health assets. (full story)
Inovio Pharmaceuticals Subsidiary Sells Animal Health Assets
PR Newswire - Tue May 27, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its 90%-owned subsidiary, VGX Animal Health, Inc. (VAH), has concluded an agreement for the sale of its animal health assets to Plumbline Life Sciences, Inc. (PLS) of Korea. The assets being transferred include an exclusive license with Inovio for animal applications of its growth hormone-releasing hormone (GHRH) technology and animal DNA vaccines plus a non-exclusive license to Inovio electroporation delivery systems. VGX Animal Health will receive $2 million in cash in multiple payments and 20% of the outstanding shares of PLS. VAH's 20% equity ownership position in PLS will be maintained without dilution up to $10 million of additional equity fundraising by PLS. Inovio Pharmaceuticals will receive milestone payments and royalties on product sales. Inovio retains the human applications of its GHRH technology. (full story)
Inovio Pharmaceuticals Breakthrough DNA-Based Monoclonal Antibody Therapy Completely Protects Animals From Lethal Viral Challenge
PR Newswire - Tue May 27, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge. In this preclinical study, a prototype DNA plasmid construct encoding for a monoclonal antibody for CHIKV envelope protein was created using Inovio's patented DNA optimization technology and delivered with its CELLECTRA® device. The results were presented as a poster at the 17th Annual Meeting of the American Society of Gene & Cell Therapy in Washington, DC. (full story)
Why Aeropostale, Inovio Pharmaceuticals, and Aruba Networks Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 23, 7:35PM CDT
Friday was a good day for the stock market on the whole, as the S&P 500 moved above 1,900 for the first time ever, and major-market benchmarks gained ground across the board. Yet, despite some of the persistently favorable trends that have helped... (full story)
Today's Top Health Care Stocks to Watch: PTC Therapeutics, Inovio Pharmaceuticals and Keryx Biopharm
George Budwell, The Motley Fool - Motley Fool - Fri May 23, 7:47AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for PTC Therapeutics , Inovio Pharmaceuticals and Keryx Biopharmaceuticals . PTC shares skyrocket after positive CHMP opinion for DMD drug PTC shares are... (full story)
Inovio Pharmaceuticals' board approves one for four reverse split
M2 - Fri May 23, 5:34AM CDT
Vaccine company Inovio Pharmaceuticals (NYSE MKT:INO) said on Friday that its shareholders approved the proposal of a one for four reverse split of its common stock at its Annual General Meeting held on 22 May 2014. (full story)
Inovio Pharmaceuticals Announces 1 For 4 Reverse Split
PR Newswire - Fri May 23, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that at the Company's Annual General Meeting held May 22, 2014, the Company's shareholders approved the proposal of a reverse split of the Company's common stock. The Company's Board of Directors subsequently approved the immediate implementation of a 1-for-4 reverse stock split of Inovio's common stock, where each 4 shares of issued and outstanding common stock and equivalents will be converted into 1 share of common stock. Following standard NYSE administrative processes, the Company plans to announce at a later time the effective date of the reverse split. (full story)
Inovio Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Wed May 21, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. Joseph Kim, President and CEO, will give a corporate presentation at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 at the Grand Hyatt Hotel in New York City. (full story)
Pre-Market Pulse on Top Gainers -- Research on Inovio Pharma, Novavax, FreeSeas, and ImmunoCellular Therapeutics
PR Newswire - Tue May 20, 10:05AM CDT
The US markets saw a positive sentiment on Monday, May 19, 2014, with the NASDAQ Composite closing at 4,125.82, up 0.86%, the Dow Jones Industrial Average ending the session 0.12% higher at 16,511.86, and the S&P 500 edging 0.38% higher to finish the trading session at 1,885.08. During the session gains in the Information Technology, Health Care, and Financials sectors positively impacted the broader market, while some retraction came in from Consumer Staples, Telecommunication Services, and Utilities sectors. A number of stocks saw large movements, including Inovio Pharmaceuticals Inc. (NYSE MKT: INO), Novavax Inc. (NASDAQ: NVAX), FreeSeas Inc. (NASDAQ: FREE) and ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC). Free technical research on INO, NVAX, FREE and IMUC can be downloaded upon signing up at: (full story)
Could These 3 Biotechs Help Fight the MERS Virus?
Leo Sun, The Motley Fool - Motley Fool - Sat May 17, 5:36PM CDT
MERS (Middle Eastern Respiratory Syndrome) has now spread to 16 countries since first appearing in Saudi Arabia in 2012. MERS causes similar symptoms as SARS (Severe Acute Respiratory Syndrome) -- including a fever, cough, and shortness of breath... (full story)
Inovio Pharmaceuticals Acquires Early Stage DNA Therapies to Treat Alzheimer's and Multiple Sclerosis
PR Newswire - Tue May 13, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today it acquired worldwide rights (excluding China) for early preclinical therapies addressing Alzheimer's disease and multiple sclerosis based on the academic research of Dr. Bin Wang, a professor at Fudan University's Shanghai Medical College. Dr. Wang is a pioneer in the field of DNA therapies, having worked closely with Dr. David Weiner at the University of Pennsylvania. Dr. Wang was the primary author on some of the earliest DNA vaccine papers and patents. In consideration for these rights, Inovio will make clinical and regulatory milestone payments to the University. (full story)
Why Inovio Pharmaceuticals Inc. Shares Briefly Tumbled Today
Sean Williams, The Motley Fool - Motley Fool - Mon May 12, 5:20PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Inovio Pharmaceuticals , a clinical-stage... (full story)
Investors look to Lighten Up on Shares of Inovio Biomedical, Shares Down 6.0% (INO)
Comtex SmarTrend(R) - Mon May 12, 12:44PM CDT
Inovio Biomedical (AMEX:INO) is one of today's worst performing low-priced stocks, down 6.0% to $2.03 on 1.2x average daily volume. Thus far today, Inovio Biomedical has traded 7.1 million shares, vs. average volume of 6.2 million shares per day. The stock has underperformed the Dow (-6.0% to the Dow's 0.6%) and underperformed the S&P 500 (-6.0% to the S&P's 0.8%) during today's trading. (full story)
Here's What You Need to Know About Inovio Pharmaceuticals' First-Quarter Earnings
George Budwell, The Motley Fool - Motley Fool - Mon May 12, 12:30PM CDT
Clinical-stage, synthetic-vaccine maker Inovio Pharmaceuticals posted first-quarter earnings this morning and gave a number of clinical updates for its growing DNA-vaccine platform. Here is what you need to know from today's release. Business... (full story)
Why Inovio Pharmaceuticals (INO) Stock Is Down Today
at The Street - Mon May 12, 9:54AM CDT
Inovio Pharmaceuticals (INO) fell Monday after the company reported first-quarter results that came up short of analysts' expectations. (full story)
Overall Average: 32% Buy
Recent stock forum discussions about INO http://investorshangout.com/search?q=INO&...mp;yt0=Go!
Today's Top Biotech Stocks: GW Pharmaceuticals, Inovio Pharmaceuticals and Novavax, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Jun 06, 7:45AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for GW Pharmaceuticals , Inovio Pharmaceuticals and Novavax Shares of GW Pharmaceuticals are up close to 6% in premarket trading this morning after the... (full story)
Inovio Pharmaceuticals sets 5 June 2014 as its reverse common stock split date
M2 - Mon Jun 02, 6:02AM CDT
Vaccines company Inovio Pharmaceuticals (NYSE MKT:INO) disclosed on Friday that its one for four reverse stock split shall become effective at 17:00 on 5 June 2014. (full story)
Today's Top Stories in Health Care: Inovio Pharmaceuticals, MannKind Corp. NewLink Genetics and Retr
George Budwell, The Motley Fool - Motley Fool - Fri May 30, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Inovio Pharmaceuticals , MannKind Corp. , NewLink Genetics and Retrophin . Inovio announces date for reverse split Clinical stage vaccinemaker... (full story)
Inovio Pharmaceuticals to implement its reverse common stock split on 5 June 2014
M2 - Fri May 30, 3:41AM CDT
Vaccines company Inovio Pharmaceuticals (NYSE MKT:INO) on Friday said that its one-for-four reverse stock split will become effective at 17:00 on 5 June 2014. (full story)
Inovio Pharmaceuticals Announces Reverse Stock Split Date
PR Newswire - Fri May 30, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014. The common stock will continue to trade under the symbol "INO." (full story)
Inovio Pharmaceuticals divests its animal health assets through its subsidiary
M2 - Tue May 27, 4:34AM CDT
Vaccines company Inovio Pharmaceuticals (NYSE MKT:INO) reported on Tuesday the completion of the sale of its animal health assets. (full story)
Inovio Pharmaceuticals Subsidiary Sells Animal Health Assets
PR Newswire - Tue May 27, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its 90%-owned subsidiary, VGX Animal Health, Inc. (VAH), has concluded an agreement for the sale of its animal health assets to Plumbline Life Sciences, Inc. (PLS) of Korea. The assets being transferred include an exclusive license with Inovio for animal applications of its growth hormone-releasing hormone (GHRH) technology and animal DNA vaccines plus a non-exclusive license to Inovio electroporation delivery systems. VGX Animal Health will receive $2 million in cash in multiple payments and 20% of the outstanding shares of PLS. VAH's 20% equity ownership position in PLS will be maintained without dilution up to $10 million of additional equity fundraising by PLS. Inovio Pharmaceuticals will receive milestone payments and royalties on product sales. Inovio retains the human applications of its GHRH technology. (full story)
Inovio Pharmaceuticals Breakthrough DNA-Based Monoclonal Antibody Therapy Completely Protects Animals From Lethal Viral Challenge
PR Newswire - Tue May 27, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge. In this preclinical study, a prototype DNA plasmid construct encoding for a monoclonal antibody for CHIKV envelope protein was created using Inovio's patented DNA optimization technology and delivered with its CELLECTRA® device. The results were presented as a poster at the 17th Annual Meeting of the American Society of Gene & Cell Therapy in Washington, DC. (full story)
Why Aeropostale, Inovio Pharmaceuticals, and Aruba Networks Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 23, 7:35PM CDT
Friday was a good day for the stock market on the whole, as the S&P 500 moved above 1,900 for the first time ever, and major-market benchmarks gained ground across the board. Yet, despite some of the persistently favorable trends that have helped... (full story)
Today's Top Health Care Stocks to Watch: PTC Therapeutics, Inovio Pharmaceuticals and Keryx Biopharm
George Budwell, The Motley Fool - Motley Fool - Fri May 23, 7:47AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for PTC Therapeutics , Inovio Pharmaceuticals and Keryx Biopharmaceuticals . PTC shares skyrocket after positive CHMP opinion for DMD drug PTC shares are... (full story)
Inovio Pharmaceuticals' board approves one for four reverse split
M2 - Fri May 23, 5:34AM CDT
Vaccine company Inovio Pharmaceuticals (NYSE MKT:INO) said on Friday that its shareholders approved the proposal of a one for four reverse split of its common stock at its Annual General Meeting held on 22 May 2014. (full story)
Inovio Pharmaceuticals Announces 1 For 4 Reverse Split
PR Newswire - Fri May 23, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that at the Company's Annual General Meeting held May 22, 2014, the Company's shareholders approved the proposal of a reverse split of the Company's common stock. The Company's Board of Directors subsequently approved the immediate implementation of a 1-for-4 reverse stock split of Inovio's common stock, where each 4 shares of issued and outstanding common stock and equivalents will be converted into 1 share of common stock. Following standard NYSE administrative processes, the Company plans to announce at a later time the effective date of the reverse split. (full story)
Inovio Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference
PR Newswire - Wed May 21, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. Joseph Kim, President and CEO, will give a corporate presentation at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 at the Grand Hyatt Hotel in New York City. (full story)
Pre-Market Pulse on Top Gainers -- Research on Inovio Pharma, Novavax, FreeSeas, and ImmunoCellular Therapeutics
PR Newswire - Tue May 20, 10:05AM CDT
The US markets saw a positive sentiment on Monday, May 19, 2014, with the NASDAQ Composite closing at 4,125.82, up 0.86%, the Dow Jones Industrial Average ending the session 0.12% higher at 16,511.86, and the S&P 500 edging 0.38% higher to finish the trading session at 1,885.08. During the session gains in the Information Technology, Health Care, and Financials sectors positively impacted the broader market, while some retraction came in from Consumer Staples, Telecommunication Services, and Utilities sectors. A number of stocks saw large movements, including Inovio Pharmaceuticals Inc. (NYSE MKT: INO), Novavax Inc. (NASDAQ: NVAX), FreeSeas Inc. (NASDAQ: FREE) and ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC). Free technical research on INO, NVAX, FREE and IMUC can be downloaded upon signing up at: (full story)
Could These 3 Biotechs Help Fight the MERS Virus?
Leo Sun, The Motley Fool - Motley Fool - Sat May 17, 5:36PM CDT
MERS (Middle Eastern Respiratory Syndrome) has now spread to 16 countries since first appearing in Saudi Arabia in 2012. MERS causes similar symptoms as SARS (Severe Acute Respiratory Syndrome) -- including a fever, cough, and shortness of breath... (full story)
Inovio Pharmaceuticals Acquires Early Stage DNA Therapies to Treat Alzheimer's and Multiple Sclerosis
PR Newswire - Tue May 13, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today it acquired worldwide rights (excluding China) for early preclinical therapies addressing Alzheimer's disease and multiple sclerosis based on the academic research of Dr. Bin Wang, a professor at Fudan University's Shanghai Medical College. Dr. Wang is a pioneer in the field of DNA therapies, having worked closely with Dr. David Weiner at the University of Pennsylvania. Dr. Wang was the primary author on some of the earliest DNA vaccine papers and patents. In consideration for these rights, Inovio will make clinical and regulatory milestone payments to the University. (full story)
Why Inovio Pharmaceuticals Inc. Shares Briefly Tumbled Today
Sean Williams, The Motley Fool - Motley Fool - Mon May 12, 5:20PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Inovio Pharmaceuticals , a clinical-stage... (full story)
Investors look to Lighten Up on Shares of Inovio Biomedical, Shares Down 6.0% (INO)
Comtex SmarTrend(R) - Mon May 12, 12:44PM CDT
Inovio Biomedical (AMEX:INO) is one of today's worst performing low-priced stocks, down 6.0% to $2.03 on 1.2x average daily volume. Thus far today, Inovio Biomedical has traded 7.1 million shares, vs. average volume of 6.2 million shares per day. The stock has underperformed the Dow (-6.0% to the Dow's 0.6%) and underperformed the S&P 500 (-6.0% to the S&P's 0.8%) during today's trading. (full story)
Here's What You Need to Know About Inovio Pharmaceuticals' First-Quarter Earnings
George Budwell, The Motley Fool - Motley Fool - Mon May 12, 12:30PM CDT
Clinical-stage, synthetic-vaccine maker Inovio Pharmaceuticals posted first-quarter earnings this morning and gave a number of clinical updates for its growing DNA-vaccine platform. Here is what you need to know from today's release. Business... (full story)
Why Inovio Pharmaceuticals (INO) Stock Is Down Today
at The Street - Mon May 12, 9:54AM CDT
Inovio Pharmaceuticals (INO) fell Monday after the company reported first-quarter results that came up short of analysts' expectations. (full story)
(0)
(0)Inovio Pharmaceuticals (INO) Stock Research Links
Scroll down for more posts ▼